An offering of floating rate senior notes due 2019, 1.4% senior notes due 2026, 1.95% senior notes due 2029 and 2.875% senior notes due 2037 has been priced by Thermo Fisher Scientific in hopes of obtaining approximately $3 billion. The company intends to use the net proceeds for partial funding of its $7.2 billion acquisition of Patheon, a pharmaceutical contract development and manufacturing firm.
Senior notes offering could pull in $3B for Thermo Fisher Scientific
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.